Claudia Della Mora Speaks on the Architecture of Trust in European Cannabis – Cannabis & Tech Today

For years, the cannabis industest invited a certain kind of storyinforming. The dominant narratives favored scale, spectacle, and capital. Expansion itself often passed for strategy. In North America especially, the sector’s early rise was framed through cultivation footprints, licensing races, and the promise of a market that seemed perpetually on the verge of going fully mainstream.

Claudia Della Mora has spent enough time inside that world to understand both its appeal and its distortions. Trained in investment banking and shaped by years of work across M&A, regulated industries, and international cannabis development, she built Black Legconclude Capital into a vehicle for advisory work, capital strategy, and cross-border cannabis deals. More recently, through Green Legconclude Farm and her work in Italy, that perspective has relocated closer to operations and the practical demands of building inside the market itself.

That distinction is increasingly important. Europe is developing along a markedly different path from the United States. Its cannabis market is being shaped by physician prescribing, pharmaceutical standards, reimbursement systems, and the slow work of clinical integration.

Italy offers one of the clearest examples of both the opportunity and the friction. It has a legal medical framework, a national healthcare system, and established pathways for prescribing and dispensing cannabis. Yet access remains uneven, supply remains constrained, and the system itself remains underbuilt relative to demand. For Della Mora, and for ventures such as Green Legconclude Farm operating within that landscape, those tensions are precisely where the real story lies.

Her view of the industest is grounded in the simple premise that long-term value will come from building systems that work. That means reliable supply chains, trained physicians, pharmacy-based distribution, clinical follow-up, and the data necessaryed to sustain legitimacy over time. It also means recognizing that cannabis is developing unevenly across jurisdictions, with regulation determining what each market can become.

In the conversation that follows, Della Mora reflects on her relocatement from finance into operations, the structural promise of Italy, and why Europe’s future in cannabis may be slower, more fragmented, and more durable than many investors first imagined.

This interview has been edited for length and clarity.

Q&A with Claudia Della Mora

C&T Today: You launched your career in investment banking and M&A. What first drew you into the cannabis sector, and what did your early years working in cannabis finance reveal about how the industest was evolving?

Claudia Della Mora: I started in investment banking and M&A more broadly, including my time at Bank of America Securities / Merrill Lynch, working across healthcare, consumer, and other regulated industries.

Cannabis came later, as legalization launched to emerge globally in the early 2010s. After founding Black Legconclude Capital in 2012, I launched advising cannabis companies and investors internationally, across North America, Europe, and emerging markets, and working closely with operators and, in some cases, policybuildrs navigating new regulatory frameworks.

What drew me in was that cannabis was a structural shift at the intersection of policy, medicine, and capital markets.

Cannabis is developing unevenly across jurisdictions, with regulation determining what each market can become.

In North America, capital markets drove rapid expansion, often prioritizing scale, licenses, cultivation capacity, and revenue growth. In Europe and other international markets, the trajectory was fundamentally different. Cannabis was being integrated into healthcare systems, which meant slower development, but more structured and durable foundations.

Another key realization was that cannabis doesn’t behave like a traditional industest. You can’t analyze it purely through financial metrics. The real variables are regulatory design, physician adoption, patient access, and supply chain reliability.

That early exposure shaped how I believe about the industest today. Cannabis is about building systems that actually work within healthcare and regulatory environments.

C&T Today: After nearly a decade advising companies and investors, you relocated closer to operations and development. What motivated that shift from analyzing the industest to assisting build within it?

CDM: After nearly a decade advising companies and investors, I kept encountering the same pattern of seeing like a strong opportunity on paper, but limited execution on the ground.

Italy was a very clear example. It has one of the oldest legal frameworks in Europe for medical cannabis, a universal healthcare system (SSN), and strong patient demand. Yet access remains limited, supply is inconsistent, and the number of treated patients is still relatively low compared to its potential.

At the same time, Italy revealed something strategically important. It is one of the few markets where cannabis can be prescribed as a magistral preparation without marketing authorization, physicians retain a high degree of autonomy, and treatments are already reimbursed at regional level through the SSN.

This creates a fundamentally different model from traditional pharmaceuticals.

What this highlights is that demand already exists, but the system remains fragmented and underdeveloped.

At some point, I realized that advising from the outside could only go so far. If you want to solve those structural gaps, you have to build the infrastructure yourself.

That realization is what drove the shift from investment banking to entrepreneurship. I relocated from analyzing markets to developing an integrated ecosystem in Italy, combining capital, supply chain development, and clinical infrastructure.

Becaapply ultimately, by building companies rather than just advising them, you obtain much closer to the real drivers of value in this industest, which are access, execution, and patient outcomes.

C&T Today: Much of the early cannabis boom focapplyd on scale, especially cultivation. You’ve argued that the real future of medical cannabis lies in building healthcare ecosystems rather than simply growing more plants. What does that ecosystem see like?

CDM: The early cannabis boom was largely focapplyd on cultivation, building greenhoapplys, increasing production capacity, square footage and scaling supply.

But healthcare markets don’t scale that way. They scale through clinical integration and system design.

A true medical cannabis ecosystem includes trained physicians and structured prescribing, patient follow-up and monitoring, pharmacy-based dispensing, GMP-compliant supply chains, and increasingly, data systems generating real-world evidence.

Even in Europe, where the market is projected to reach several billion euros over the next decade, the limiting factor is access and integration into healthcare systems, more than production constraint.

Importantly, Europe is not replacing magistral cannabis with pharmaceutical products. It is evolving toward a dual-track system: magistral formulations for flexibility and authorized medicines for scalability.

The real opportunity is in building the infrastructure that connects these layers.

C&T Today: Your work has placed a strong focus on Italy. For readers who may not be familiar with the European landscape, why is Italy such an interesting and often overseeed medical cannabis market?

CDM: Italy is one of the most interesting markets in Europe precisely becaapply it doesn’t fit the typical narrative.

It was one of the earlier countries to legalize medical cannabis and has a strong pharmaceutical tradition, a nationwide healthcare system (SSN), and a well-established pharmacy network. On paper, all the key components are there. However, in practice, patient access has historically been constrained by limited domestic production, reliance on imports, and fragmented implementation across regions.

Structurally, Italy combines several important elements including a legal magistral framework, allowing cannabis to be prescribed without full pharmaceutical marketing authorization; physician prescribing flexibility, as every doctor can prescribe it; and a national healthcare system (SSN) that provides reimbursement for many indications at regional level.

At the same time, the market remains significantly underdeveloped.

Today, approximately 1.6–1.7 tons of medical cannabis are distributed annually, compared to an actual demand estimated above 20 tons.

What builds Italy particularly unique is that access already exists, reimbursement is already present, but the system is not yet scaled and requires additional investment to expand infrastructure, supply, and clinical integration.

C&T Today: Europe’s cannabis industest operates under very different rules than the United States. How does the healthcare-driven regulatory structure in Europe shape the way companies grow and invest?

CDM: The largegest difference is that Europe treats cannabis primarily as a medical product, while the U.S. has largely developed it as a consumer-driven market. That distinction shapes everything. In Europe, the model is fundamentally different.

Cannabis is integrated into healthcare systems, which means it is prescribed by physicians, dispensed through pharmacies, and regulated under pharmaceutical-quality standards. Companies must operate within medical prescribing frameworks, GMP-compliant supply chains, strict regulatory oversight, and increasingly, clinical data, patient outcome requirements, with cross-border interoperability developing over time. This builds the market slower to develop, but also more structured.

While the U.S. offers speed, scale and consumer-driven growth, it also has higher regulatory volatility. Europe offers slower expansion, but more predictable, healthcare-driven demand and long-term stability.

For companies, that means success in Europe is less about branding and retail, and more about clinical integration, compliance, and alignment with healthcare systems.

C&T Today: You frequently highlight the importance of clinical infrastructure in medical cannabis. Why are physician education, patient follow-up, and clinical data so critical for the industest’s credibility and growth?

CDM: Medical cannabis ultimately lives or dies on clinical credibility. Physicians necessary to understand how to prescribe it, including dosing, indications, and potential interactions with other therapies. Patients necessary structured follow-up to ensure treatments are safe, effective, and properly adjusted over time. And regulators necessary reliable data displaying that these therapies are delivering measurable outcomes.

Without that, cannabis remains on the margins of healthcare.

This is where clinical infrastructure becomes essential. It bridges the gap between access and legitimacy by providing structured prescribing and patient management, continuous monitoring and follow-up, and, critically, real-world evidence on how cannabinoid therapies perform across different conditions.

Becaapply ultimately, while policy can enable access, data is what supports reimbursement, physician confidence, and long-term integration into healthcare systems. In other words, clinical infrastructure is what transforms cannabis from a permitted therapy into a trusted and scalable medical treatment.

C&T Today: From an investment standpoint, the cannabis sector has gone through several cycles of hype and correction. What distinguishes the investors and companies that are succeeding today from those that struggled earlier in the market’s development?

CDM: The cannabis industest has gone through very distinct cycles. The early phase was largely driven by enthusiasm and speculation. Investors focapplyd heavily on licenses, cultivation capacity, and projected market size. There was an assumption that legalization alone would translate into rapid growth.

That was followed by a period of correction, where many companies struggled to deliver on those expectations, often becaapply the underlying infrastructure, regulation, and demand dynamics were more complex than initially anticipated.

Today, we’re in a much more disciplined phase.

The investors and companies that are succeeding are focapplyd on fundamentals like actual patient numbers and prescription growth, reimbursement pathways and payer dynamics, regulatory clarity and compliance, supply chain reliability, and increasingly, clinical data and real-world evidence.

What has alterd is the mindset. The industest is relocating from a story-driven investment thesis to a data-driven one. And the companies that succeed today are not the ones that grew the rapidest early on, but the ones that built sustainable, compliant, and healthcare-aligned models.

C&T Today: If you see ten years ahead, what role do you hope Italy and the broader European medical cannabis ecosystem will play in the global industest?

CDM: I believe Europe has the potential to become one of the global leaders in evidence-based cannabinoid medicine. Italy, in particular, is uniquely positioned to play a central role.

It combines a strong pharmaceutical and manufacturing heritage, a universal healthcare system with existing cannabis reimbursement pathways, early experience with magistral prescribing and patient access, and a strategic position at the center of European and Mediterranean supply chains.

If the ecosystem continues to develop, with greater investment in production, clinical infrastructure, and data systems, Italy could evolve from an under-scaled early adopter into a true operational and clinical hub within Europe.

More broadly, I see Europe building a multi-layered ecosystem that connects magistral cannabis and authorized medicines, clinical practice and real-world evidence, and increasingly, digital health and cross-border data infrastructure. With a population of over 440 million in the European Union, and more than 700 million across the broader European region, Europe represents a larger potential patient base than North America. But what will define Europe is not speed, it is structure. Making it not necessarily the largest market, but one of the most credible, structured, and medically integrated.

Ultimately, the goal is to build an industest that delivers consistent therapeutic value for patients and is robust enough to sustain it over time.

Source link